drugset / Trial / NCT01186068

Dose Response Study of Patients With Erythematous Rosacea

NCT01186068 ↗

Phase 2 Completed 175 enrolled Vicept Therapeutics, Inc. Accenture · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.

Timeline

Start
2010-08
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject TETRASUL Small molecule 0.01 % —
Subject TETRASUL Small molecule 0.06 % —
Subject TETRASUL Small molecule 0.1 % —
Subject TETRASUL Small molecule 0.15 % —

Indications